Efficacy of octreotide and sclerotherapy in the treatment of acute variceal bleeding in cirrhotic patients: A prospective, multicentric, and randomized clinical trial

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 4, 2000, Pages 419-425

  Bildozola, M ^a,b,c   Kravetz, David ^a,b,c   Argonz, J ^a,b,c   Romero, G ^a,b,c   Suarez, A ^a,b,c   Jmelnitzky, A ^a,b,c   Fainberg, M ^a,b,c   Fassio, E ^a,b,c   Berreta, J ^a,b,c   Landeira, G ^a,b,c   Martinez, H ^a,b,c   Bosco, A ^a,b,c   Guevara, M ^a,b,c   Valero, J ^a,b,c   Chopita, N ^a,b,c   Berenstein, G ^a,b,c   Terg, R ^a,b,c  

^a HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^b Hospital Interzonal Gral San Martin   (Argentina)

^c HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

Author keywords

Octreotide; Sclerotherapy; Variceal bleeding

Indexed keywords

OCTREOTIDE;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLEROTHERAPY; STOMACH VARICES; TREATMENT OUTCOME;

EID: 0034071978     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750024001     Document Type: Article

References (34)

1. 1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
2. 2. Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodes J, Wright SC, et al. Propranolol in the prevention of the first haemorrhage from oesophagogastric varices. A multicenter randomized clinical trial. Hepatology 1991;13:902-12.
3. 3. Bosch J, D'Amico G, Luca A, Garcia Pagan JC, Feu F, Escorsell A. Drug therapy for variceal haemorrhage. In: Bosch J, Groszmann RJ, editors. Portal hypertension. Pathophysiology and treatment. London: Blackwell Scientific Publications; 1994. p. 108-23.
4. 4. Kravetz D, Bosch J, Teres J, Rodes J. Comparison of intravenous somatostatin and vasopressin infusion in the treatment of acute variceal hemorrhage. Hepatology 1984;4:442-6.
5. 5. Westaby D, Hayes PC, Gimson ES, Polson RJ, Williams R. Controlled clinical trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989;9:274-7.
6. 6. Teres J, Baroni R, Bordas JM, Visa J, Pera C, Rodes J. Randomized trial of portocaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. J Hepatol 1987;4:159-67.
7. 7. Avgerinos A, Armonis A, Raptis S. Somatostatin or octreotide versus endoscopic sclerotherapy in acute variceal haemorrhage: a meta-analysis study. J Hepatol 1995;22:247-8.
8. 8. Kutz K, Nüesch E, Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986;21 Suppl 119:65-72.
9. 9. Jenkins SA, Baxter JN, Corbett WA, Shields R. Effects of a somatostatin analogue SMS 201-995 on hepatic hemodynamic in the pig and on intravariceal pressure in man. Br J Surg 1985;72:1009-12.
10. 10. Warhen J, Eriksson LS. The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism en healthy subjects and patients with cirrhosis. Scand J Gastroenterol 1986;21 Suppl 119:103-8.
11. 11. Mc Kee R. A study of octreotide in oesophageal varices. Digestion 1990;45 Suppl:60-4.
12. 12. Mc Cormick PA, Dick R, Siringo S, Wagstaff D, Chesta J, McIntyre N, et al. Octreotide reduces azygos blood flow in cirrhotic patients with portal hypertension. Eur J Gastroenterol Hepatol 1990;2:489-92.
13. 13. Lin HC, Tsai YT, Lee FY, Lee SD, Hsia HC, Lin WJ, et al. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis. Gastroenterology 1992;103:229-34.
14. 14. Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide. Gut 1996;38:129-34.
15. 15. Burroughs AK. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures. International Octreotide Varices Study Group [abstract]. Hepatology 1996;24:352A.
16. 16. Jenkins SA, Copeland G, Kingsworth A, Shields R. A prospective randomized controlled clinical trial comparing sandoslatin and injection sclerotherapy in the control of acute variceal haemorrhage: an interim report [abstract]. Gut 1992;33: F221.
17. 17. Poo JL, Bosques F, Garduño R, Marin E, Morán MA, Bobadilla J, et al. Octreotide versus emergency sclerotherapy in acute variceal hemorrhage in liver cirrhosis. A randomized, multicenter study [abstract]. Gastroenterology 1996;110:A1297.
18. 18. Sung JJ, Chung SCS, Lai CW, Chan FKL, Leung JWC, Yung MY. Octreotide infusion or emergency sclerotherapy for variceal hemorrhage. Lancet 1993;342:637-11.
19. 19. De Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, et al. Consensus report. Definitions, methodology and therapeutic strategies in portal hypertension: a consensus development workshop. J Hepatol 1992;15:256-61.
20. 20. Navasa M, Bosch J, Chesta J, Bru C, Pizcueta P, García-Pagán JC, et al. Haemodynamic effects of subcutaneous administration of SMS 201-995 a long acting somatostatin analog in patients with cirrhosis and portal hypertension. J Hepatol 1988;7 Suppl 1:S64.
21. 21. Zironi G, Rossi C, Siringo S, Galaverni C, Gaiani S, Piscaglia F, et al. Short-and long hemodynamic response to octreotide in portal hypertensive patients: a double-blind, controlled study. Liver 1996;16:225-34.
22. 22. Jenkins SA, Shields R, Davies M, Elias E, Turbull AJ, Bassendine MF, et al. A multicentre randomized trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage. Gut 1997;41:526-33.
23. 23. Planas R, Quer JC, Boix J, Canet J, Armengol M, Cabre E, et al. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding. Hepatology 1994;20:370-5.
24. 24. Shields R, Jenkins SA, Baxter JN, Kingsnorth AN, Ellenbogen S, Makin CA, et al. A prospective randomized controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in the control of bleeding oesophageal varices. J Hepatol 1992;16:128-37.
25. 25. Burroughs A, McCormick P, Hughes M, Sprengers D, D'Heygere F, McIntyre N. Randomized, double blind, placebo-controlled trial of somatostatin for variceal bleeding. Gastroenterology 1990;99:1388-95.
26. 26. Fleischer D. Etiology and prevalence of severe persistent upper gastrointestinal bleeding. Gastroenterology 1983;84:538-43.
27. 27. Escorsell A, Feu F, García-Pagán JC, Luca A, Bandi JC, Casado M, et al. Hemodynamic effects of octreotide in cirrhotic patients with portal hypertension. A double-blind study [abstract]. J Hepatol 1995;23 Suppl 1:85.
28. 28. Eriksson LS, Brundin T, Söderlund C, Wahren J. Haemodynamic effects of long-acting somatostatin analogue in patients with liver cirrhosis. Scand J Gastroenterol 1987;22:919-25.
29. 29. Cello JP, Chan MF. Octreotide therapy for variceal hemorrhage. Digestion 1993;54 Suppl 1:20-6.
30. 30. Lin HC, Yang MC-M, Hou M-C, Li SM, Huang Y-T, Yu P-C, et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996;23:537-43.
31. 31. Silvain C, Carpentier S, Sautereau D, Czernichow B, Métreau JM, Fort E, et al. Terlipressin plus transdermal nitroglycerin vs. octreotide in the control of acute bleeding from esophageal varices: a multicenter randomized trial. Hepatology 1993;18: 61-5.
32. 32. Terblanche J, Burroughs AK, Hobbs KEF. Controversies in the management of bleeding esophageal varices. N Engl J Med 1989;320:1393-8.
33. 33. Levacher S, Lefoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat J-L. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8.
34. 34. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomized trial. Lancet 1997;350: 1495-9.